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Introduction 
 Parkinson’s disease (PD) is one of the most prevalent neurodegenerative 
diseases.  It is characterized by its main symptom of a tremor that usually starts in one 
limb.  The four cardinal symptoms of PD are tremor, rigidity, bradykinesia, and postural 
instability.  While the four cardinal symptoms are all motor symptoms there are non-
motor symptoms for PD which include cognitive changes, sleeping disorders, 
lightheadedness, early satiety, and mood disorders. PD is characterized by 
dopaminergic (DA) neuron loss and the accumulation of Lewy bodies (LB) which are 
predominantly composed of α-synuclein (α-Syn) protein.  
α-Syn is a protein found abundantly in the brain.  It is characterized by an 
amphipathic lysine-rich amino terminus which plays a role in modulating its interactions 
with membranes.  This protein is also characterized by its acidic carboxy-terminal tail, 
which plays a role in regulating its nuclear localization and interactions with metals, 
small molecules and proteins (Lashuel et al.). The misfolding of α-Syn can cause 
aggregates allowing damage to the cells that it is found in, which has been shown to be 
a cause of PD.  Mutation in α-Syn was first noted in 1997, where an amino acid 
substitution change was noted producing an autosomal-dominant pattern of inheritance 
for PD (Stefanis). There are two types of PD, familial PD where a mutation can be 
passed on through generations. Sporadic PD, the second type of PD, is when the 
mutations occur in patients without the familial connection to PD. Mutations in the 
leucine-rich repeat kinase 2 (LRRK2) have also been linked to the cause of autosomal 
dominant PD.  Additionally, LRRK2 has been linked to tau and α-Syn pathologies, 
suggesting that possibly LRRK2 mutations are players in cell degeneration or cell death. 
Mitochondrial dysfunction can also lead to PD, therefore the pathway that leads to this 
dysfunction needs to be explored more.  
 
Drosophila as an animal model 
 Drosophila melanogaster is known to be one of the most common model 
organisms used for different biomedical science research purposes.  Advantages to 
using the Drosophila model is its low cost, fast generation time, easy to care for, and is 
an excellent tool for genetic manipulation (Tolwinski). Since 75% of human disease 
genes have homologues in Drosophila, it is a powerful model organism to study human 
neurodegenerative diseases.  In the Drosophila model, transgenic lines are created with 
mutated human α-Syn genes which display similar symptoms/characteristics of PD 
found in humans. Symptoms include the decreased locomotor function, and 
characteristics include the loss of DA neurons (Aryal and Lee). 
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α-Synuclein 
α-Syn toxicity may be one of the causes for PD as accumulation of α-Syn protein 
can lead to the formation of LB and cause cell damage or cell death.  The cause of α-
Syn protein accumulation is not well known.  MicroRNAs (miRNAs) mediate the 
expression of many genes and are involved in cell homeostasis.  Dysregulated 
microRNAs have been a suggested link to PD, and many of these miRNAs are found in 
the blood and brain of PD patients (Kong et al.).  
 In one study, using the Drosophila model, PD induced flies were produced that 
had phenotypes of deteriorating climbing ability consistent with symptoms of PD flies. 
To determine the effect that these types of miRNAs have on PD, analysis of all the 
miRNAs that were expressed in the PD flies and the control flies were quantified. 154 
miRNAs were identified, and 5 miRNAs (dme-miR-133-3p, dme-miR-137-3p, dme-miR-
13b-3p, dme-miR-932-5p, dme-miR-1008-5p) were found to be more expressed in the 
PD flies (Kong et al.).  The targets for these miRNAs were found to be enriched in 
neuron- related biological processes.  Examining targets in the neuroactive ligand-
receptor interaction pathway, they found that the five targets associated with the 
upregulated 5 miRNAs were downregulated in the PD flies, which showed that these 5 
miRNAs are dysregulated. (Kong et al.).  The suggested explanation for miRNA 
dysregulation is the toxicity that occurs with α-Syn forming aggregates.  
 In the literature there are studies that look to understand the pathway or 
mechanism of a disease.  One such study involving α-Syn’s mechanism studied 
Glucocerebrosidase deficiency as a possible pathway. Mutations in the GBA1 gene have 
been shown to have a tight connection with α-Syn toxicity (Suzuki et al.). Homozygous 
mutations in the GBA1 gene have been shown to lead to decreased enzyme activity 
(Glucocerebrosidase (GCase)) and tend to lead to Gaucher’s disease which have a 
higher tendency to develop parkinsonism; these patients tend to have α-Syn positive 
Lewy bodies in their brains (Suzuki et al.).  PD patients with heterozygous mutations in 
the GBA1 gene tend to develop diffuse Lewy body pathology which is linked to earlier 
onset of the disease. The molecular mechanism of the connection between a deficiency 
in Gcase and α-Syn induced PD in vivo was not well known. The objective of the study 
was to discover the relationship between this decreased activity of GCase and α-Syn 
toxicity as well as the molecular mechanisms involved using the Drosophila model 
(Suzuki et al.).  To investigate GCase deficiency effects on α-Syn toxicity transgenic 
RNAi flies that have inverted repeat RNA that targets the Drosophila homolog of the 
GBA1 gene were generated.  The dGBA1a-IR (dGBA1a-RNAi flies) or dGBA1b-IR 
(dGBA1b-RNAi flies) flies showed 81-92% decrease in GCase activity (Suzuki et al.).  
Wild type α-Syn expressing flies were crossed with the dGBA1a-RNAi and dGBA1b-
RNAi flies to obtain progeny that have co-expressing α-Syn and dGBA1a-IR (Suzuki et 
al.). A climbing assay was performed to determine the locomotor dysfunction.  The 
progeny’s climbing ability was significantly declined from two to three weeks after 
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eclosion and rapidly decreased from then on. Immunohistochemical staining for tyrosine 
hydroxylase which is essential in the synthesis of dopamine (DA) showed that the RNAi 
flies have fewer DA neurons than the control flies, demonstrating the tendency to 
exacerbate the α-Syn toxicity (Suzuki et al.). To see if an accelerated accumulation of α-
Syn is what causes the toxicity, an immunoblotting analysis was performed.  With the 
GBA1 knockdown, there was no significant increase in α-Syn, showing that the GCase 
deficiency does not lead to the accumulation of α-Syn (Suzuki et al.).  Instead it was 
suggested that the number of α-Syn is not what ties into its toxicity. A proteinase K (PK) 
treatment was applied to the experimental strain lines which showed GCase deficiency 
may promote conformational changes in α-Syn to PK-resistant α-Syn, which could lead 
into the α-Syn toxicity. This accumulation of PK-resistant α-Syn suggested that GlcCer, 
a substrate of GCase, could possibly affect the conversion of α-Syn to its PK-resistant 
form.  Staining and chromatography showed that the GlcCer accumulates when there is 
a deficiency of GCase (Suzuki et al.).  PK digestion with GlcCer showed that GlcCer 
directly promotes the conversion of α-Syn to its PK- resistant form (Suzuki et al.). Fly 
lines that contained inverse repeats of the Drosophila homolog of β-galactosidase were 
also observed. This knockdown of β-galactosidase was analyzed with its conversion of 
α-Syn to its PK-resistant form. The results were very similar to those of the GlcCer 
conversion effects. The main difference was that dimer formation was not affected. 
Results showed that the β-gal deficiency mediates the conversion of α-Syn to its PK-
resistant form, then increasing the toxicity of α-Syn (Suzuki et al.). The study showed 
that GCase deficiency played a role in the mechanism of α-Syn toxicity.  
 Another study that looked at the mechanism of α-Syn toxicity studied the role of 
vacuolar protein sorting 35 (Vps35).  This protein is a part of a cargo recognition subunit 
of a retromer, aspartyl protease cathepsin D (CTSD). This retromer is a major player in 
the degradation of long-lived proteins such as α-Syn which suggested that VPS35 is 
directly involved with this pathway. The study’s idea was to interfere with the VPS35 
which then would stop the maturation of the CTSD protein, possibly allowing for the 
accumulation of the α-Syn (Miura et al.). To create VPS35 deficient cells in the fly model, 
two siRNAs were used to target VPS35.  This created an increase in pre-mature pro-
CTSD and a decrease in the overall mature CTSD in the cells (Miura et al.).  To see if 
CTSD does promote the degradation of α-Syn, CTSD was then overexpressed in the 
cells, which showed an increase in mature CTSD in the cells and a significant decrease 
in the long version α-Syn (Miura et al.).  To see if the deficiency in this VPS35 retromer 
links to the formation of these PD phenotypes (loss of motor skills), VPS35 was silenced 
in cells which then caused an increase in α-Syn.  The eyes of the flies were then 
analyzed and found to have a different phenotype than that of the control flies, resulting 
in experimental group to have eye degeneration (Miura et al.).  VPS35 deficient flies had 
higher age- dependent loss of climbing ability (Miura et al.).  Thus the link between 
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VPS35  and α-Syn which leads to PD- like phenotypes can be shown in this study. 
However, their mechanisms are not well known and needs further studies.  
Other types of studies focus on the suppression of PD symptoms in Drosophila. 
One study focused on synphilin-1, another component of Lewy bodies.  synphilin-1 is a 
major part of LB which is a pathological aspect of PD.  synphilin-1 also interacts with α-
Syn which when mutated causes PD.  synphilin-1 and α-Syn each by themselves 
causes their own host of issues, and toxicity. However, when these two proteins are co-
expressed, they seem to cancel each other out in the Drosophila model (Vargas et al.).  
The first round of testing in this study was to direct its expression pan-neurally by 
means of Elav-GAL4 driver.  The results showed that the overexpression of α-Syn and 
synphilin-1 are very similar in that both showed slight vacuolization and marble-like 
inclusions in the cytoplasm (Vargas et al.).  The co-expression of these two proteins 
showed a suppression of the vacuolization and marble-like inclusions phenotype and 
one that is closer to the wild-type phenotype.  When this transgene expression is driven 
in DA neurons, the survivability of these neurons showed that the overexpression of just 
one of these proteins causes a toxic effect on the neurons whereas the co-expression of 
these proteins promotes an environment where more of the neurons can survive 
(Vargas et al.).  The motility of the flies that overexpressed just one protein was 
compared to those that co-expressed and control flies. The results showed a significant 
difference in motility between those that expressed one protein and those that co-
expressed both proteins.  The co-expression flies seem to reverse the adverse effects 
of the one protein flies which have a less likely outcome of survival and motility (Vargas 
et al.). Drosophila electroretinogram is an electric field measurement that has transients 
appear at light stimulation.  α-Syn or synphilin-1 overexpressing flies when treated with 
L-Dopa/carbidopa reverts the effect of the transgenes (Vargas et al.). Overexpression of 
either of these two proteins damaged DA neurons and not other photoreceptors, 
whereas the co-expression of both suppressed PD- like symptoms.  
 Another study focused on the use of a kinase to suppress the PD symptoms in 
the Drosophila model.  PINK1 (PTEN-induced putative kinase 1) has been localized to 
the mitochondria and is speculated to be involved in the Mitochondria’s protection.  
Mutations in this gene have been known to lead to oxidative stress, therefore it has 
been thought that PINK1 has a role in preventing oxidative stress.  In the same 
pathway, parkin has been shown to be able to rescue α-Syn induced PD- like 
phenotype.  The possibility that parkin and PINK1 act in a similar manner suggests that 
PINK1 can protect or rescue an αSyn induced PD phenotype.  A motility assay was 
preformed and flies with overexpressed PINK1 showed suppression of PD phenotype 
by losing their climbing ability.  In flies with overexpressed α-Syn, rough eye phenotype 
could be observed. This phenotype was partially rescued in the overexpressed PINK1 
flies (Todd and Staveley). However, PINK1 overexpression in control flies also led to a 
partial suppression of the rough eye phenotype, which means PINK1 also counteracted 
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the effects of Gal4 (Todd and Staveley).  In the α-Syn fly model retinal degeneration 
could occurred, with intact retina at 3 days and then premature deteriorated at 30 days. 
When PINK1 is overexpressed, the retina was intact at 3 days and past 30 days (Todd 
and Staveley), showing the suppression of the damaging effects of the α-Syn.  
 One last study that focused on α-Syn suppression in the Drosophila model using 
ubiquitin linkages.  PD is pathologically marked by mitochondria dysfunction, as well as 
oxidative stress, deposition of aggregates (LB), and degeneration of DA neurons. LB 
are known to be made of α-Syn proteins.  It is known that two pathways target oxidized 
damaged or misfolded proteins for degradation, those being ubiquitin proteasomal 
system (UPS) and autophagy lysosomal pathway (ALP). These pathways also have 
been known to be associated with neurodegeneration.  The main objective of the study 
was to determine if UPS or different types of ubiquitin linkages affect α-Syn toxicity in 
the PD Drosophila model (Lee et al.).  To test the role of ubiquitin linkages with the 
suppression of α-Syn toxicity, the retinal degeneration phenotype in the Drosophila 
model was observed.  Wild type α-Syn was expressed alone in one set of flies and as 
previously known, the results showed the degeneration of rhabdomeres in the eyes of 
the flies (Lee et al.).  However, in the flies that were expressed with wild type α-Syn and 
ubiquitin linkage proteins there was a bit of contrast, those that co-expressed either K48 
or K63R with the wild type α-Syn showed suppression of α-Syn induced toxicity 
phenotype, degeneration of rhabdomeres in the eyes (Lee et al.). The other two 
ubiquitin linkages that were co-expressed with the wild type α-Syn (K48R and K63) 
differed in results as the degeneration of rhabdomeres in the eyes still did (Lee et al.).  
One phenotype that is commonly observed in the Drosophila PD model is the 
loss of climbing ability which is age dependent.  The flies were co-expressed with wild 
type α-Syn and the mutant ubiquitin linkages to explore the link between mutant 
ubiquitin linkages and suppression of α-Syn toxicity. Those that had K48 or K63R had a 
suppression effect on the α-Syn induced phenotype and a higher level of climbing ability 
at an older age was observed.  Those with the K48R or K63 co-expressed had a much 
lower level of climbing ability at an older age, comparably like that of the flies that just 
had the wild type α-Syn expressed (Lee et al.).  The research team believed that this 
suppression effect of α-Syn induced phenotype was dependent on K48.  The K48 
ubiquitin dependence suggested that the way in which this works is through the 
facilitation of degradation of cellular proteins. To test this hypothesis, a Ub-R-GFP 
degron was constructed, and when the transgenic flies co-expressed wild type α-Syn, 
Ub-R-GFP and K48 promoted the degradation of Ub-R-GFP more than that of the other 
co-expressions of K33 and K63 (Lee et al.).  However, the amount of α-Syn was 
unaffected by these constructs added to the transgenic flies.  A similar experiment was 
conducted with GFPu and similar results were observed (Lee et al.).  Since the 
degradation of these proteins was enhanced with those flies that expressed wild type or 
K48, the proteasome activity in these types of flies was tested.  However, the 
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proteasomal activity is inconsistent with what was thought to have happened. Overall, 
the study found that the expression of ubiquitin linkages, specifically K48 was able to 
offer neuroprotection against α-Syn toxicity that occurs in the cell (Lee et al.).  
  
LRRK2 
 Another cause of PD is a mutation that occurs within LRRK2. This mutation has 
been shown to cause autosomal dominant PD (Liu et al.). Transgenic expression of 
LRRK2 and its mutants in the Drosophila model bring about loss of dopaminergic 
neurons and behavioral deficits which make them great models for PD.  One study 
aimed to explore how inhibitors for LRRK2 could possibly rescue the loss of DA neurons 
and PD- like phenotypes.  Inhibitors like GW5074 and sorafenib were shown to have 
effects on the LRRK2 and were able to rescue PD like phenotypes in the Drosophila 
model (Liu et al.). The model of C. elegans showed that the population that expressed 
LRRK2 had significant DA degeneration whereas those with LRRK2 inhibitor treatment 
showed significant DA survival and rescue (Liu et al.).  To test if LRRK2 induced PD is 
dependent on kinase activity, a mutation was introduced that abolished enhanced 
kinase activity.  As the flies increase in age the amount of degenerated DA neurons 
increases as well.  Climbing assays and survival of flies with these two inhibitors 
expressed were measured. The two inhibitors impacted the transgenic flies, in that 
survival increased and climbing impairment decreased.  The GW5074 inhibitor was 
slightly stronger than that of the sorafenib inhibitor (Liu et al.).  Both inhibitors were also 
found to reduce the amount of lost DA neurons and decrease the amount of kinase 
activity in the population. The GW5074 being slightly stronger in all these areas then 
that of sorafenib (Liu et al.).  
 Another study that looked at treatment on LRRK2 induced PD aimed to 
determine how LRRK2 interacts with Vps35 along with Vps29 and Vps 26 (Linhart et 
al.).  The PD symptom in LRRK2 mutants is black lesions in the eye, this is a marker for 
neuron death occurring in later eye development.  Transgenic flies that expressed a 
higher level of Vps35 or Vps26 rescued this black lesion phenotype that occurs with the 
LRRK2 mutant (Linhart et al.). Loss of DA neurons is a pathological marker for PD 
which creates the motor symptoms that are seen in PD patients, Drosophila motor skills 
can be measured using a negative geotaxis climbing assay.  LRRK2 mutant flies had a 
lower climbing ability compared to the control flies while LRRK2 mutant flies with 
overexpressed Vps35 or Vps26 were able to recover their climbing ability (Linhart et 
al.). The basic survival of these flies was also observed and those with VPs35 or VPs26 
overexpression had a significantly longer survival than those without (Linhart et al.).   
Other LRRK2 mutants, were also observed and the results showed similar results, 
further solidifying these results.  The rescue of climbing ability then is not dependent on 
the kinase dominant mutant, providing evidence that LRRK2 may play a role in the 
retromer dependent pathway in PD (Linhart et al.).  Knockdown of Vps26 was observed 
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and had a very significant phenotype in the eye (black lesions) which was found to be 
non-additive (Linhart et al.).  Non-additive effects were also found when Vps35 or Vps29 
were knocked down, which then impaired the locomotor function of these flies (Linhart 
et al.).  LRRK2, based on these results, is in the same pathway as these core 
components of the cargo recognition subunit.  Rotenone is a pesticide and can be used 
to model PD. Applying a rotenone treatment to control flies brought down the survival 
rate of those flies. Overexpressing Vps35 in normal flies with rotenone treatment mildly 
protected the flies (Linhart et al.). Co-expression of LRRK2 and Vps35 protected the 
flies from the rotenone toxicity, much more than any of the other treated groups (Linhart 
et al.). Climbing assay on these flies had similar results.  Knocking down Vps35 did not 
have a significant effect on the flies climbing ability or survival in comparison to the 
other groups of flies (Linhart et al.). Vps35 and LRRK2, based on these results, interact 
in DA neurons, possibly importantly under cellular stress.  
Another study investigated LRRK2 mutation and its link to PD treatment 
investigating melatonin as a solution. Melatonin is a naturally produced compound in 
many organisms which regulates the wake/sleep cycle (Ran et al.).  Although the 
suggestion to use melatonin as a possible therapy for PD or other neurodegenerative 
diseases has been made, the mechanisms of action remain elusive. The aim of the 
study was to identify the molecular mechanisms of melatonin as a therapy for PD in the 
Drosophila model (Ran et al.).  Using both behavioral tests and other assays for 
analysis, data in the study suggested that the long-term memory of PD flies would be 
affected.  When long-term memory was studied in the transgenic flies, flies that 
expressed LRRK2 had a significantly reduced capacity in long term memory compared 
to the control flies.  However, flies with melatonin treatment had a significantly long-term 
memory, close to the level of the control flies (Ran et al.).  The mechanism of how 
melatonin works in affecting the LRRK2 has been suggested to be by regulating the 
extracellular calcium channel activity (Ran et al.). Current density of the calcium 
channels was observed in different groups and the groups with expression of LRRK2 
had a significantly increased current density compared to that of the control group (Ran 
et al.).  The group that had melatonin treatment has decreased current density when 
compared to the non-melatonin treatment group.  The mean open time was also lower 
in the melatonin treatment group (Ran et al.).  Overall, the study showed that melatonin 
treatment rescued the effects of LRRK2 induced dysregulation, including rescuing long-
term memory, suggesting that melatonin could possibly be used as a novel therapy for 
PD.  
 
 
hUCP2 (human uncoupling protein 2) 
Another study aimed to study the role that mitochondrial uncoupling proteins 
(UCPs), specifically ucp2, has in neuroprotection in the Drosophila model of PD (Islam 
          MaryAnn Jaquith  
9 
et al.). UCPs promote proton leakage, which disrupts the proton gradient in the ETC, 
resulting in uncoupled substrate oxidation and ATP phosphorylation. UCP2 expression 
was found to be induced after mimics of epilepsy, stroke, and seizures in mouse 
models.  A study was preformed to determine the neuroprotective role that human 
UCP2 (hUCP2) in a Drosophila model for PD.  As chronic exposure to rotenone leads to 
DA neuron death, transgenic flies that expressed hUCP2 were treated with rotenone 
along with a control group without treatment (Islam et al.).  Those with hUCP2 were 
found to be neuroprotection against DA degeneration when compared with the control 
group.  As DA degeneration by rotenone exposure can lead to motor deficiency, 
negative geotaxis assays were preformed and those with hUCP2 expression showed a 
higher retention of climbing ability (Islam et al.).  ATP levels were also examined and 
hUCP2 flies have higher ATP than control flies.  This higher amount of ATP in the 
hUCP2 flies could be a result of higher mitochondrial function or mitochondrial 
biogenesis.  Using real time PCR and transmission electron microscopy, the team was 
able to determine that other processes besides mitochondrial biogenesis is what is 
producing this elevated level of ATP (Islam et al.).  To determine if mitochondrial 
function is at play, quantitative real time analysis was done and found that there was an 
increase in complex 1 activity but not complex3 (Islam et al.)  Spargel a known protein 
that regulates mitochondrial activity but not biogenesis, found to be significantly higher 
in the hUCP2 flies (Islam et al.).  Spargel linked protein Tfam was also found to be 
significantly higher.  These results suggested hUCP2 reduced rotenone oxidative 
damage and plays a neuroprotective role in the Drosophila model of PD.  
 
 
Conclusion 
 Overall, the literature in Drosophila research on Parkinson’s disease is diverse. 
The main genetic cause of PD would seem to be the α-Syn component.  The 
aggregation of these misfolded proteins causes cellular death and the loss of the DA 
neurons.  The studies show that there are ways to rescue the PD effect of this 
pathology.  Some of those ways include co-expression of both α-Syn and other proteins 
or overexpression of other proteins.  Other studies that investigated α-Syn pathology 
also showed insight into the interactions or mechanisms that α-Syn takes in PD models. 
Including the how deficiency of GCase and Vps35 can contribute to the pathology of 
PD.  
 The second most prevalent genetic cause of PD being that of LRRK2 mutations. 
This disrupted kinase ends up being a player in loss of DA neurons as well.  The studies 
have shown through the Drosophila model of PD that there are ways to rescue this 
pathway and ways to possibly create therapies.  Those possible options being shown in 
the results of Vps35, inhibitors and melatonin as treatment options.  
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 Lastly looking at the Drosophila model of PD with respects to hUCP2 a 
neuroprotective approach. Overall many approaches to looking into treatment for PD 
are conducted, which seem to be all centered around rescuing the phenotypes or 
symptoms in this model. The way that PD is being investigated in this model, as seen 
seems to be bringing about some great results. 
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